Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Price Up 4.1%

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)’s share price was up 4.1% during mid-day trading on Friday . The company traded as high as $164.00 and last traded at $163.80. Approximately 49,017 shares changed hands during mid-day trading, a decline of 93% from the average daily volume of 708,264 shares. The stock had previously closed at $157.40.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on ALNY shares. HC Wainwright lifted their target price on Alnylam Pharmaceuticals from $395.00 to $400.00 and gave the company a “buy” rating in a research report on Tuesday, May 7th. Canaccord Genuity Group reissued a “buy” rating and issued a $283.00 target price on shares of Alnylam Pharmaceuticals in a research report on Friday. BMO Capital Markets reissued an “outperform” rating and issued a $234.00 target price on shares of Alnylam Pharmaceuticals in a research report on Wednesday, March 27th. William Blair reissued an “outperform” rating on shares of Alnylam Pharmaceuticals in a research report on Monday, April 8th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $225.00 price target on shares of Alnylam Pharmaceuticals in a research report on Friday, May 3rd. Seven research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $220.12.

Alnylam Pharmaceuticals Stock Performance

The firm has a market capitalization of $20.96 billion, a price-to-earnings ratio of -61.83 and a beta of 0.30. The business has a fifty day moving average of $150.49 and a two-hundred day moving average of $162.35.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.23. The business had revenue of $494.33 million for the quarter, compared to analyst estimates of $428.01 million. The firm’s revenue was up 54.8% compared to the same quarter last year. During the same period in the previous year, the firm posted ($1.40) earnings per share. As a group, sell-side analysts predict that Alnylam Pharmaceuticals, Inc. will post -3.74 EPS for the current fiscal year.

Insider Activity at Alnylam Pharmaceuticals

In related news, Director Amy W. Schulman sold 21,700 shares of the business’s stock in a transaction on Wednesday, May 29th. The stock was sold at an average price of $148.60, for a total value of $3,224,620.00. Following the completion of the sale, the director now directly owns 8,436 shares in the company, valued at approximately $1,253,589.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 1.50% of the stock is currently owned by corporate insiders.

Institutional Trading of Alnylam Pharmaceuticals

Institutional investors have recently modified their holdings of the stock. Allspring Global Investments Holdings LLC increased its holdings in Alnylam Pharmaceuticals by 572.0% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 143 shares in the last quarter. Altitude Crest Partners Inc. acquired a new stake in shares of Alnylam Pharmaceuticals in the first quarter valued at about $30,000. Quent Capital LLC boosted its position in shares of Alnylam Pharmaceuticals by 246.0% during the 4th quarter. Quent Capital LLC now owns 173 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 123 shares in the last quarter. Anchor Investment Management LLC bought a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter valued at about $38,000. Finally, Robeco Institutional Asset Management B.V. boosted its position in shares of Alnylam Pharmaceuticals by 155.7% during the 4th quarter. Robeco Institutional Asset Management B.V. now owns 20,549 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 12,513 shares in the last quarter. 92.97% of the stock is currently owned by institutional investors.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.